share_log

BetterLife Pharma Inc. (OTCMKTS:BETRF) Sees Large Decrease in Short Interest

Defense World ·  Oct 3, 2022 04:41

BetterLife Pharma Inc. (OTCMKTS:BETRF – Get Rating) was the target of a significant drop in short interest during the month of September. As of September 15th, there was short interest totalling 51,500 shares, a drop of 5.5% from the August 31st total of 54,500 shares. Based on an average trading volume of 64,500 shares, the short-interest ratio is currently 0.8 days.

BetterLife Pharma Stock Performance

BETRF opened at $0.14 on Monday. The company's 50 day simple moving average is $0.14 and its 200 day simple moving average is $0.11. BetterLife Pharma has a 1 year low of $0.05 and a 1 year high of $0.30. The stock has a market capitalization of $7.31 million, a PE ratio of -1.58 and a beta of 2.72.

Get BetterLife Pharma alerts:

BetterLife Pharma Company Profile

(Get Rating)

BetterLife Pharma Inc, a biotechnology company, engages in the development and commercialization of compounds for the treatment of neurological disorders in Canada and internationally. It is involved in refining and developing drug candidates from a set of complementary interferon-based technologies that have the potential to engage the immune system to fight virus infections.

Featured Articles

  • Get a free copy of the StockNews.com research report on BetterLife Pharma (BETRF)
  • Archer Daniels Midland: Dividend Hero With 49 Years Of Increases
  • Will Fully Autonomous Tractors Make Deere the Tesla of Farming?
  • Magna International is Your Auto and EV One-Stop Shop Stock
  • EV Battery Maker Freyr Set For Major Global Expansion
  • MarketBeat: Week in Review 9/26 – 9/30

Receive News & Ratings for BetterLife Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BetterLife Pharma and related companies with MarketBeat.com's FREE daily email newsletter.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment